Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
7.98
+0.08 (1.01%)
Dec 5, 2025, 4:00 PM EST - Market closed

Gyre Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22
Net Income
6.6512.09-92.932.3
Depreciation & Amortization
2.331.591.111.13
Loss (Gain) From Sale of Assets
-0.073.340
Asset Writedown & Restructuring Costs
--83.1-
Loss (Gain) on Equity Investments
0.070.041.310.25
Stock-Based Compensation
3.130.837.2813.37
Provision & Write-off of Bad Debts
0.040.17-0.060.02
Other Operating Activities
4.014.446.021.4
Change in Accounts Receivable
-7.13-5.260.29-7.92
Change in Inventory
-2.54-2.141.75-0.88
Change in Accounts Payable
0.26-0.250.19-0.11
Change in Income Taxes
-0.15-2.173-1.34
Change in Other Net Operating Assets
-2.78-13.0511.492.46
Operating Cash Flow
3.88-3.6425.8910.68
Operating Cash Flow Growth
56.52%-142.50%-
Capital Expenditures
-0.98-2.32-8.52-4.99
Sale of Property, Plant & Equipment
0.160.40.66-
Cash Acquisitions
--5.46-
Divestitures
---0.57-
Sale (Purchase) of Intangibles
-1.55-0.81-0.07-0.01
Investment in Securities
-1.96-17.16-16.74-8.82
Investing Cash Flow
-4.33-19.88-19.76-13.81
Issuance of Common Stock
26.882.64--
Other Financing Activities
-1.85-0.54--
Financing Cash Flow
25.022.12.5-
Foreign Exchange Rate Adjustments
-0.04-0.27-0.3-1.89
Net Cash Flow
24.54-21.78.33-5.03
Free Cash Flow
2.9-5.9617.385.69
Free Cash Flow Growth
--205.25%-
Free Cash Flow Margin
2.70%-5.63%15.32%5.56%
Free Cash Flow Per Share
0.03-0.060.260.07
Cash Income Tax Paid
5.258.526.356.31
Levered Free Cash Flow
2.9-620.67-
Unlevered Free Cash Flow
2.9-620.67-
Change in Working Capital
-12.35-22.8616.72-7.8
Source: S&P Capital IQ. Standard template. Financial Sources.